Kimberly Frazier
Primary Care · Lansing, MINPI 1225420243
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.9% of the total across 598 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Johnson & Johnson at 33.3% of the total. Reporting peaked in 2022 at $2,293 and has fallen 62.1% since, to $869 in 2025. Among primary care clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 598 payments — averaging $13.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$3K
- AbbVie$1K
- Novartis$940
- Amgen$799
- UCB, Inc.$510
- Pfizer$390
- plus $1K from 17 others
What the payments were for
- Food & beverage$7,70496%
- Education$3334%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 262 | $2,677 |
| AbbVie | 129 | $1,342 |
| Novartis | 45 | $940 |
| Amgen | 44 | $799 |
| UCB, Inc. | 29 | $510 |
| Pfizer | 25 | $390 |
| ANI Pharmaceuticals, Inc. | 11 | $259 |
| E.r. Squibb & Sons, L.L.C. | 13 | $213 |
| Janssen Scientific Affairs, LLC | 2 | $134 |
| Organon | 6 | $130 |
| AstraZeneca | 3 | $118 |
| Lilly USA, LLC | 5 | $99 |
| Aurinia Pharma U.S., Inc. | 4 | $75 |
| Actelion Pharmaceuticals US, Inc. | 3 | $60 |
| Mallinckrodt Hospital Products Inc. | 3 | $57 |
| GSK | 4 | $49 |
| Boehringer Ingelheim | 2 | $45 |
| Sobi, Inc | 2 | $36 |
| Genentech USA, Inc. | 2 | $27 |
| United Therapeutics Corporation | 1 | $25 |
| Sandoz | 1 | $18 |
| Biocon Biologics Inc | 1 | $18 |
| Alvogen Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SIMPONI ARIA$245
- Tremfya$118
- STELARA$118
- Skyrizi$105
- PURIFIED CORTROPHIN GEL$101
How this compares
$8,037 in reported general payments places this provider in the 95th percentile of 292 primary care providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 34 | $227,230 |
| EnbrelEtanercept | 18 | $204,342 |
| Cosentyx Sensoready PenSecukinumab | 17 | $152,188 |
| Humira(Cf)Adalimumab | 16 | $113,052 |
| OrenciaAbatacept | 12 | $69,436 |
| Hydroxychloroquine Sulfate | 300 | $24,234 |
| Lidocaine | 27 | $15,169 |
| MitigareColchicine | 23 | $11,977 |
| MethotrexateMethotrexate Sodium | 181 | $8,536 |
| Cevimeline Hcl | 30 | $5,792 |
| Leflunomide | 80 | $4,839 |
| Prednisone | 290 | $3,112 |
| Celecoxib | 47 | $3,110 |
| Sulfasalazine | 55 | $2,378 |
| Levocarnitine | 11 | $2,067 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenEnbrel | $799 | $204,34218 claims |
| AbbVieHumira(Cf) | $1,342 | $113,05216 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $213 | $69,43612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 292 primary care providers in Michigan.
Other primary care in Lansing
- Marie Sighe-NzokouLansing$16K
- Julie AlvaradoLansing$6K
- Jessica DelcorvoLansing$4K
- Donna HamillGrosse Pointe$17K
- Alexandria SchwabBay City$10K
- Amy HenryRochester Hills$10K
- Claire GebaraWaterford$9K
- Vanita RobinsonDetroit$9K
- Mary BoudreauMason$9K
- Rachel HetznerMadison Heights$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.